Description: Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Home Page: www.photocure.com
Hoffsveien 4
Oslo,
0275
Norway
Phone:
47 22 06 22 10
Officers
| Name | Title |
|---|---|
| Mr. Daniel Schneider | President & CEO |
| Mr. Erik Dahl | Chief Financial Officer |
| Mr. David Moskowitz | Head of Investor Relations |
| Anja Gossens-von der Heidt | Head of Global Human Resources |
| Dr. Anders Neijber M.D. | Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D |
| Mr. Tolv Hillestad | Group Controller |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 85.8 |
| Price-to-Book MRQ: | 2.7198 |
| Price-to-Sales TTM: | 0.2324 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 102 |